Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24995656 | 0.82 | ELANE (0.37) | LMNAELANEADORA2AADORA1 | |
| SCHEMBL21101028 | 0.78 | ADORA2A (0.47) | ELANEADORA2AADORA1 | |
| SCHEMBL24943858 | 0.74 | ALDH1A1 (0.41) | LMNAADORA2A | |
| SCHEMBL21341735 | 0.74 | LMNA (0.36) | LMNAELANEADORA2AADORA1 | |
| SCHEMBL19565807 | 0.74 | CHEK1 (0.45) | LMNA | |
| SCHEMBL24175509 | 0.71 | MAPK1 (0.38) | LMNAELANEADORA2AADORA1 | |
| SCHEMBL10139174 | 0.71 | ADORA2A (0.36) | LMNAELANEADORA2AADORA1 | |
| SCHEMBL18701492 | 0.69 | ADORA2A (0.36) | LMNAELANEADORA2AADORA1 | |
| SCHEMBL20618771 | 0.67 | — | — | |
| SCHEMBL21101027 | 0.67 | USP2 (0.31) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | LMNA 1748/4885ELANE 3101/4885ADORA2A 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.